Return On Capital Employed Overview: Eli Lilly

Looking at Q3, Eli Lilly LLY earned $1.28 billion, a 6.81% increase from the preceding quarter. Eli Lilly also posted a total of $5.74 billion in sales, a 4.4% increase since Q2. Eli Lilly earned $1.20 billion, and sales totaled $5.50 billion in Q2.

What Is Return On Capital Employed?

Changes in earnings and sales indicate shifts in Eli Lilly's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Eli Lilly posted an ROCE of 0.26%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Eli Lilly is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.

For Eli Lilly, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.

Q3 Earnings Recap

Eli Lilly reported Q3 earnings per share at $1.54/share, which did not meet analyst predictions of $1.71/share.